AR076259A2 - Derivados de 3,5-dietil-1h-pirazol-4-il-oxi nitrilos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones por hiv - Google Patents
Derivados de 3,5-dietil-1h-pirazol-4-il-oxi nitrilos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones por hivInfo
- Publication number
- AR076259A2 AR076259A2 ARP100100890A ARP100100890A AR076259A2 AR 076259 A2 AR076259 A2 AR 076259A2 AR P100100890 A ARP100100890 A AR P100100890A AR P100100890 A ARP100100890 A AR P100100890A AR 076259 A2 AR076259 A2 AR 076259A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- heteroatom
- optionally substituted
- conr5r5
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 13
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- -1 homopiperidinyl Chemical group 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000002393 azetidinyl group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado por la formula (1) o una sal farmacéuticamente aceptable del mismo, donde: R1 es H, alquilo C1-6, cicloalquilo C3-7 o -OR7, dicho alquilo C1-6 y cicloalquilo C3-7, pueden estar opcionalmente sustituidos por halo, -CN, -OR10, S(O)xR10, -CO2R10, -CONR5R10, -OCONR5R10, -NR5CO2R10, -NR10R11, -NR5COR10, -SO2NR5R10, -NR5CONR5R10, -NR5SO2R10 o R10; R2 es H, alquilo C1-6, alquenilo C3-6 o R9, dicho alquilo C1-6 están opcionalmente sustituido por halo, -OR5, -OR12, -CN, -CO2R7, -OCONR5R5, -CONR5R5, -C(=NR5)NR5OR5, -CONR5NR5R5, -NR6R6, -NR5R12, -NR5COR5, -NR5COR8, -NR5COR12, -NR5CO2R5, -NR5CONR5R5, -SO2NR5R5, -NR5SO2R5, R8 o R9; R3 es H o alquilo C1-6, dicho alquilo C1-6 está opcionalmente sustituido por halo, -CN, -OR5, -CO2R5, -CONR5R5, -OCONR5R5, -NR5CO2R5, -NR6R6, -NR5COR5, -SO2NR5R5, -NR5CONR5R5, -NR5SO2R5, R8 o R9; R4 es fenilo sustituido por R8, halo, -CN, alquilo C1-6, C1-6 haloalquilo C1-6, cicloalquilo C3-7 o alcoxi C1-6; cada R5 esta cada uno independientemente H, alquilo C1-6 o cicloalquilo C3-7 o, cuando dos grupos R5 están unidos al mismo átomo de nitrogeno, aquellos dos grupos tomados juntos con el átomo de nitrogeno al cual están unidos representan azetidinilo, pirrolidinilo, piperidinilo, homopiperidinilo, piperazinilo, homopiperazinilo o morfolinilo, dicho azetidinilo, pirrolidinilo, piperidinilo, homopiperidinilo, piperazinilo, homopiperazinilo y morfolinilo están opcionalmente sustituidos por C1-6 alquilo C1-6 o cicloalquilo C3-7; cada R6 es independientemente tanto H, alquilo C1-6 o cicloalquilo C3-7; R7 es alquilo C1-6 o cicloalquilo C3-7; R8 es un grupo heterocíclico aromático, de cinco o seis miembros que contiene (i) de 1 a 4 heteroátomo(s) de nitrogeno o (ii) 1 o 2 heteroátomo(s) de nitrogeno y 1 un heteroátomo de oxígeno o 1 heteroátomo de azufre o (iii) 1 o 2 heteroátomo(s) de oxigeno o azufre, dicho grupo heterocíclico esta opcionalmente sustituido por halo, oxo, -CN, -COR5, -CONR5R5, -SO2NR5R5, -NR5SO2R5, -OR5, -NR5R5, -(alquileno C1-6)-NR5R5, alquilo C1-6, fluoro alquilo C1-6 o cicloalquilo C3-7; R9 es un grupo heterocíclico saturado o parcialmente insaturado de cuatro a siete miembros, que contiene (i) 1 o 2 heteroátomo(s) de nitrogeno o (ii) 1 heteroátomo(s) de nitrogeno y 1 heteroátomo de oxígeno o 1 heteroátomo de azufre o (iii) 1 heteroátomo(s) de oxígeno o un heteroátomo(s) azufre, dicho grupo heterocíclico estando opcionalmente sustituido por oxo, alquilo C1-6 cicloalquilo C3-7, -SO2R5, -CONR5R5, -COOR5, -CO-(alquileno)-OR5 o -COR5 y opcionalmente sustituido sobre un átomo de carbono que no es adyacente a un heteroátomo por halo, -OR5, -NR5R5, -NR5COR5, -NR5COOR5, -NR5CONR5R5, -NR5SO2R5 o -CN; R10 es H, R8, R9, R13, alquilo C1-6, cicloalquilo C3-7 o -(alquilo C1-6)-(cicloalquilo C3-7), dicho alquilo C1-6 y cicloalquilo C3-7 estando opcionalmente sustituidos por -OR5, -OR13, R8, R9, R13 o -COR13; R11 es H, alquilo C1-6 o cicloalquilo C3-7, dicho alquilo C1-6 y cicloalquilo C3-7 estando opcionalmente sustituido por -OR5, -NR5R5, -NR5COR5, -CONR5R5, R8 o R9; R12 es alquilo C1-6 sustituido por R8, R9, -OR5, -CONR5R5, -NR5COR5 o -NR5R5; R13 es fenilo opcionalmente sustituido por halo, -CN, -COR5, -CONR5R5, -SO2NR5R5, -NR5SO2R5, -OR5, -NR5R5, -(alquileno C1-6)-NR5R5, alquilo C1-6, haloalquilo C1-6 o cicloalquilo C3-7; y x es 0, 1 o 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0108999A GB0108999D0 (en) | 2001-04-10 | 2001-04-10 | Pyrazole derivatives |
| GB0127426A GB0127426D0 (en) | 2001-11-15 | 2001-11-15 | Pyrazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076259A2 true AR076259A2 (es) | 2011-06-01 |
Family
ID=26245955
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101281A AR037319A1 (es) | 2001-04-10 | 2002-04-08 | Compuestos derivados de pirazol, procedimientos para la preparacion, intermediarios, composiciones farmaceuticas, procedimiento de tratamiento |
| ARP100100890A AR076259A2 (es) | 2001-04-10 | 2010-03-19 | Derivados de 3,5-dietil-1h-pirazol-4-il-oxi nitrilos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones por hiv |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101281A AR037319A1 (es) | 2001-04-10 | 2002-04-08 | Compuestos derivados de pirazol, procedimientos para la preparacion, intermediarios, composiciones farmaceuticas, procedimiento de tratamiento |
Country Status (42)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3806090B2 (ja) * | 2001-04-10 | 2006-08-09 | ファイザー・インク | Ｈｉｖ関連疾患治療用のピラゾール誘導体 |
| CA2471880A1 (en) * | 2001-12-28 | 2003-07-17 | Bayer Pharmaceuticals Corporation | 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| JP4228587B2 (ja) | 2002-05-22 | 2009-02-25 | 昭和電工株式会社 | アミノメチル基含有ベンズアミド化合物の製造方法 |
| GB0221477D0 (en) * | 2002-09-16 | 2002-10-23 | Pfizer Ltd | Chemical compounds |
| US20040132793A1 (en) * | 2002-09-16 | 2004-07-08 | Pfizer Inc. | Pyrazole derivatives |
| GB0223232D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| GB0223234D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| MXPA05010081A (es) | 2003-03-24 | 2005-11-23 | Hoffmann La Roche | Bencil-piridazinonas como inhibidores de transcriptasa inversa. |
| WO2005013888A2 (en) * | 2003-05-14 | 2005-02-17 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7220772B2 (en) | 2003-09-05 | 2007-05-22 | Pfizer, Inc. | Pyrazole derivatives |
| US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| JP3997255B2 (ja) | 2004-02-13 | 2007-10-24 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲンレセプターモジュレーター |
| WO2005100305A1 (en) | 2004-04-13 | 2005-10-27 | Warner-Lambert Company Llc | Androgen modulators |
| WO2005102990A1 (en) | 2004-04-22 | 2005-11-03 | Warner-Lambert Company Llc | Androgen modulators |
| AR048650A1 (es) * | 2004-05-04 | 2006-05-10 | Tibotec Pharm Ltd | Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih |
| BRPI0513020A (pt) | 2004-07-08 | 2008-04-22 | Warner Lambert Co | moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação |
| CA2604218A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| PL1948615T3 (pl) * | 2005-11-08 | 2012-04-30 | Pfizer Ltd | Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych |
| US7875636B2 (en) * | 2006-04-12 | 2011-01-25 | Merck Sharp & Dohme Corp. | Pyridyl amide T-type calcium channel antagonists |
| CN101501002B (zh) | 2006-08-16 | 2012-06-27 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
| US20080096950A1 (en) * | 2006-10-19 | 2008-04-24 | Karl Richard Gibson | Compounds Useful In Therapy |
| US9280685B2 (en) * | 2006-12-08 | 2016-03-08 | Johnnie R. Jackson | System and method for portable medical records |
| WO2008135824A1 (en) * | 2007-05-02 | 2008-11-13 | Pfizer Limited | Oxyalkylpyrazole compounds useful in therapy |
| JP2010530863A (ja) | 2007-06-22 | 2010-09-16 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての尿素及びカルバマート誘導体 |
| CA2702126A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| CA2701594C (en) | 2007-10-24 | 2014-02-18 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide t-type calcium channel antagonists |
| WO2009080534A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| PH12012501537A1 (en) | 2010-01-27 | 2018-02-07 | Viiv Healthcare Co | Antiviral therapy |
| AU2011241103A1 (en) * | 2010-04-13 | 2012-11-08 | Sentreheart, Inc. | Methods and devices for treating atrial fibrillation |
| EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
| UY33766A (es) * | 2010-12-06 | 2012-06-29 | Glaxo Group Ltd | COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2 |
| WO2013050873A1 (en) | 2011-10-07 | 2013-04-11 | Phivco Uk Limited | Process for the preparation of lersivirine |
| WO2013057593A1 (en) | 2011-10-07 | 2013-04-25 | Phivco Uk Limited | Process for the preparation of lersivirine |
| WO2013050884A1 (en) | 2011-10-07 | 2013-04-11 | Phivco Uk Limited | Process for the preparation of lersivirine |
| EP2716632A1 (en) | 2012-10-05 | 2014-04-09 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| US9695127B2 (en) | 2012-11-08 | 2017-07-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compounds for treating HIV and methods for using the compounds |
| US10026064B2 (en) | 2013-09-13 | 2018-07-17 | Microsoft Technology Licensing, Llc | Automatically recommending updates based on stored lifecycle information |
| JPWO2015060348A1 (ja) * | 2013-10-23 | 2017-03-09 | 大日本住友製薬株式会社 | 縮合ピラゾール誘導体 |
| EP3140289A1 (en) * | 2014-05-06 | 2017-03-15 | E. I. du Pont de Nemours and Company | Fungicidal pyrazoles |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| ES2968785T3 (es) * | 2014-10-31 | 2024-05-14 | Hoffmann La Roche | Nuevos compuestos de piridiniloxi- y feniloxipirazolilo |
| US9925190B2 (en) | 2015-02-16 | 2018-03-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting HIV-1 Nef |
| JOP20180092A1 (ar) * | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| AU2019217875A1 (en) | 2018-02-06 | 2020-08-20 | Icahn School Of Medicine At Mount Sinai | Repeat RNA as biomarkers of tumor immune response |
| KR102114389B1 (ko) * | 2018-05-02 | 2020-05-25 | 이화여자대학교 산학협력단 | 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2020056564A1 (zh) * | 2018-09-17 | 2020-03-26 | 南通纺织丝绸产业技术研究院 | 基于金属氢化物/钯化合物体系制备1,3-二羰基化合物的方法 |
| JP2022504982A (ja) * | 2018-10-18 | 2022-01-13 | 南京聖和薬業股▲ふん▼有限公司 | ＴＧＦ－βＲ１阻害剤としての化合物及びその応用 |
| CN113527306B (zh) * | 2020-04-17 | 2025-06-24 | 南京圣和药物研发有限公司 | 喹啉类TGF-β1抑制剂的晶型 |
| CN113527304B (zh) * | 2020-04-17 | 2025-08-12 | 南京圣和药物研发有限公司 | 喹啉类TGF-β1抑制剂的制备方法 |
| EP4541790A1 (en) | 2022-06-15 | 2025-04-23 | Nissan Chemical Corporation | Pyrazole compound, production intermediate thereof, and pest control agent |
| KR20250164815A (ko) | 2023-03-31 | 2025-11-25 | 닛산 가가쿠 가부시키가이샤 | 피라졸 화합물 및 유해 생물 방제제 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3303200A (en) * | 1963-11-05 | 1967-02-07 | American Home Prod | Pyrazole-1-ethanol derivatives |
| US3963742A (en) * | 1974-07-12 | 1976-06-15 | American Cyanamid Company | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents |
| US4009277A (en) * | 1975-01-17 | 1977-02-22 | American Cyanamid Company | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents |
| US4041046A (en) | 1975-06-06 | 1977-08-09 | American Cyanamid Company | 1,2-Dialkyl-3,4,5-trisubstituted pyrazole compounds |
| US4000301A (en) | 1975-11-14 | 1976-12-28 | American Cyanamid Company | Fungicidal use of 4-alkoxypyrazoles |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH0565237A (ja) | 1991-09-10 | 1993-03-19 | Mitsubishi Heavy Ind Ltd | メタノールを媒体としたエネルギ供給方法 |
| FR2682379B1 (fr) * | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | Nouveaux phenylpyrazoles fongicides. |
| WO1994022830A1 (en) | 1993-03-31 | 1994-10-13 | Smithkline Beecham Corporation | Chemical compounds |
| FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
| DE69408950T2 (de) | 1993-12-14 | 1998-10-15 | Mitsubishi Chem Corp | N-Pyrazolylcarbamatderivate und Fungizide für Landwirtschaft und Gartenbau, die diese als aktive Bestandteile erhalten, Produktion und Zwischenprodukte |
| FR2722369B1 (fr) | 1994-07-13 | 1998-07-10 | Rhone Poulenc Agrochimie | Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides |
| MX9702030A (es) | 1994-09-26 | 1997-06-28 | Shionogi & Co | Derivado de imidazol. |
| TW343232B (en) * | 1994-10-13 | 1998-10-21 | Chisso Corp | Difluorooxymethane derivative and liquid crystal composition |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2876779A1 (en) * | 2000-05-12 | 2001-11-22 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
| GB0016787D0 (en) * | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
| JP3806090B2 (ja) * | 2001-04-10 | 2006-08-09 | ファイザー・インク | Ｈｉｖ関連疾患治療用のピラゾール誘導体 |
-
2002
- 2002-04-04 JP JP2002583387A patent/JP3806090B2/ja not_active Expired - Lifetime
- 2002-04-04 SK SK1244-2003A patent/SK287858B6/sk unknown
- 2002-04-04 ES ES02708600T patent/ES2283532T3/es not_active Expired - Lifetime
- 2002-04-04 AU AU2002242926A patent/AU2002242926B2/en not_active Expired
- 2002-04-04 CZ CZ2003-2676A patent/CZ305099B6/cs not_active IP Right Cessation
- 2002-04-04 EP EP02708600A patent/EP1377556B1/en not_active Expired - Lifetime
- 2002-04-04 ES ES06126433T patent/ES2385659T3/es not_active Expired - Lifetime
- 2002-04-04 DK DK02708600T patent/DK1377556T3/da active
- 2002-04-04 PL PL365026A patent/PL216985B1/pl unknown
- 2002-04-04 PL PL396946A patent/PL217224B1/pl unknown
- 2002-04-04 KR KR1020037013352A patent/KR100569324B1/ko not_active Expired - Fee Related
- 2002-04-04 MX MXPA03009380A patent/MXPA03009380A/es active IP Right Grant
- 2002-04-04 OA OA1200300258A patent/OA12501A/en unknown
- 2002-04-04 BR BR0208811-8 patent/BRPI0208811B8/pt not_active IP Right Cessation
- 2002-04-04 PT PT02708600T patent/PT1377556E/pt unknown
- 2002-04-04 AT AT02708600T patent/ATE358669T1/de active
- 2002-04-04 DE DE60219292T patent/DE60219292T2/de not_active Expired - Lifetime
- 2002-04-04 IL IL15787502A patent/IL157875A0/xx unknown
- 2002-04-04 EA EA200300943A patent/EA007184B1/ru not_active IP Right Cessation
- 2002-04-04 RS YUP-775/03A patent/RS51166B/sr unknown
- 2002-04-04 NZ NZ529403A patent/NZ529403A/en not_active IP Right Cessation
- 2002-04-04 HR HR20030783A patent/HRP20030783B1/xx not_active IP Right Cessation
- 2002-04-04 CN CNB028116259A patent/CN100408564C/zh not_active Expired - Lifetime
- 2002-04-04 EE EEP200300497A patent/EE05400B1/xx unknown
- 2002-04-04 HU HU0303735A patent/HU229025B1/hu unknown
- 2002-04-04 CA CA002443449A patent/CA2443449C/en not_active Expired - Lifetime
- 2002-04-04 WO PCT/IB2002/001234 patent/WO2002085860A1/en not_active Ceased
- 2002-04-04 ME MEP-758/08A patent/ME00558A/xx unknown
- 2002-04-04 SI SI200230986T patent/SI1762567T1/sl unknown
- 2002-04-04 EP EP06126433A patent/EP1762567B1/en not_active Expired - Lifetime
- 2002-04-04 DK DK06126433.9T patent/DK1762567T3/da active
- 2002-04-04 GE GE5299A patent/GEP20053619B/en unknown
- 2002-04-04 SI SI200230529T patent/SI1377556T1/sl unknown
- 2002-04-04 PL PL398536A patent/PL217629B1/pl unknown
- 2002-04-04 AT AT06126433T patent/ATE556059T1/de active
- 2002-04-04 PT PT06126433T patent/PT1762567E/pt unknown
- 2002-04-05 US US10/118,512 patent/US7109228B2/en not_active Expired - Lifetime
- 2002-04-08 AR ARP020101281A patent/AR037319A1/es active IP Right Grant
- 2002-04-08 MY MYPI20021264A patent/MY146669A/en unknown
- 2002-04-09 TW TW091107115A patent/TWI333488B/zh not_active IP Right Cessation
- 2002-04-09 UY UY27248A patent/UY27248A1/es not_active IP Right Cessation
- 2002-04-10 PE PE2002000297A patent/PE20021056A1/es active IP Right Grant
- 2002-04-10 DO DO2002000378A patent/DOP2002000378A/es unknown
- 2002-04-10 PA PA20028543601A patent/PA8543601A1/es unknown
-
2003
- 2003-09-04 IS IS6939A patent/IS2734B/is unknown
- 2003-09-09 CR CR7069A patent/CR7069A/es unknown
- 2003-09-11 IL IL157875A patent/IL157875A/en active IP Right Grant
- 2003-10-06 MA MA27336A patent/MA27009A1/fr unknown
- 2003-10-08 BG BG108244A patent/BG66349B1/bg unknown
- 2003-10-09 NO NO20034523A patent/NO326518B1/no not_active IP Right Cessation
-
2005
- 2005-06-20 US US11/157,340 patent/US7435728B2/en not_active Expired - Lifetime
-
2007
- 2007-05-10 CY CY20071100627T patent/CY1107626T1/el unknown
-
2008
- 2008-08-25 US US12/197,655 patent/US8063044B2/en not_active Expired - Fee Related
-
2010
- 2010-03-19 AR ARP100100890A patent/AR076259A2/es active IP Right Grant
-
2011
- 2011-10-07 US US13/269,278 patent/US20120029192A1/en not_active Abandoned
-
2012
- 2012-06-27 CY CY20121100571T patent/CY1113515T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076259A2 (es) | Derivados de 3,5-dietil-1h-pirazol-4-il-oxi nitrilos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones por hiv | |
| AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
| AR039554A1 (es) | Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR069740A1 (es) | Compuestos nucleosidos antivirales | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| FI865037A7 (fi) | Mikrobicida kompositioner. | |
| AR062499A1 (es) | Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos. | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| BRPI0612888B8 (pt) | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| AR059778A1 (es) | Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios. | |
| AR061374A1 (es) | Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| CO5031250A1 (es) | Compuesto farmaceutico | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR030698A1 (es) | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas,, una composicion farmaceutica, uso de los mismos para preparar un medicamento como agentes antivirales y un metodo para inhibir una adn polimerasa viral | |
| AR041546A1 (es) | Agentes antibacterianos de tetrahidroquiolina triciclicos | |
| AR044821A1 (es) | 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4 | |
| AR001061A1 (es) | Composición fungicida sinergica procedimiento par a combatir hongos nocivos uso de los compuestos que integran dicha composición como componentes sinergicos de la misma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |